Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells.

Mutations in the CEBPA gene are present in 7%-10% of human patients with acute myeloid leukemia (AML). However, no genetic models exist that demonstrate their etiological relevance. To mimic the most common mutations affecting CEBPA-that is, those leading to loss of the 42 kDa C/EBPalpha isoform (p42) while retaining the 30kDa isoform (p30)-we modified the mouse Cebpa locus to express only p30. p30 supported the formation of granulocyte-macrophage progenitors. However, p42 was required for control of myeloid progenitor proliferation, and p42-deficient mice developed AML with complete penetrance. p42-deficient leukemia could be transferred by a Mac1+c-Kit+ population that gave rise only to myeloid cells in recipient mice. Expression profiling of this population against normal Mac1+c-Kit+ progenitors revealed a signature shared with MLL-AF9-transformed AML.

[1]  Pu Zhang,et al.  Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia , 2001, Nature Genetics.

[2]  D. Liang,et al.  AML patients with CEBPα mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: a comparative analysis on paired diagnosis and relapse samples , 2006, Leukemia.

[3]  C. Nerlov.  C/EBPα mutations in acute myeloid leukaemias , 2004, Nature Reviews Cancer.

[4]  I. Weissman,et al.  Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. , 2003, Genes & development.

[5]  J. Kutok,et al.  Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[6]  B. Porse,et al.  E2F Repression by C/EBPα Is Required for Adipogenesis and Granulopoiesis In Vivo , 2001, Cell.

[7]  V. Heath,et al.  C/EBPα deficiency results in hyperproliferation of hematopoietic progenitor cells and disrupts macrophage development in vitro and in vivo , 2004 .

[8]  O. MacDougald,et al.  A 30-kDa alternative translation product of the CCAAT / enhancer binding protein a message : Transcriptional activator lacking antimitotic activity ( 3 T 3L 1 cells / preadipocyte / adipocyte / differentiation / liver ) , 2005 .

[9]  M. Cleary,et al.  Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. , 2007, Genes & development.

[10]  M. Cleary,et al.  Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. , 2003, Genes & development.

[11]  MOZ-TIF2, but Not BCR-ABL, Confers Properties of Leukemic Stem Cells to Committed Murine Hematopoietic Progenitors. , 2004 .

[12]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Marie S. Hasemann,et al.  Loss of C/EBPα cell cycle control increases myeloid progenitor proliferation and transforms the neutrophil granulocyte lineage , 2005, The Journal of experimental medicine.

[14]  M. Cleary,et al.  Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. , 2006, Cancer cell.

[15]  D. Tenen,et al.  Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Bradley,et al.  Impaired energy homeostasis in C/EBP alpha knockout mice , 1995, Science.

[17]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[18]  C. Preudhomme,et al.  CEBPA point mutations in hematological malignancies , 2005, Leukemia.

[19]  A. Ganser,et al.  Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia , 2003, British journal of haematology.

[20]  S. Langabeer,et al.  Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. , 2002, Blood.

[21]  Jih-Luh Tang,et al.  Characterization of CEBPA Mutations in Acute Myeloid Leukemia: Most Patients with CEBPA Mutations Have Biallelic Mutations and Show a Distinct Immunophenotype of the Leukemic Cells , 2005, Clinical Cancer Research.

[22]  V. Heath,et al.  C/EBPalpha deficiency results in hyperproliferation of hematopoietic progenitor cells and disrupts macrophage development in vitro and in vivo. , 2004, Blood.

[23]  S. Fröhling,et al.  CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Z. Piao,et al.  Clinical significance of Y chromosome loss in hematologic disease , 2000, Genes, chromosomes & cancer.

[25]  L. Kjeldsen,et al.  Characterization of two ELISAs for NGAL, a newly described lipocalin in human neutrophils. , 1996, Journal of immunological methods.

[26]  T. Lister,et al.  AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. , 2006, Blood.

[27]  T. Golub,et al.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 , 2006, Nature.

[28]  D. Ledbetter,et al.  Multicolor Spectral Karyotyping of Human Chromosomes , 1996, Science.

[29]  Pu Zhang,et al.  Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. , 2004, Immunity.

[30]  B. Porse,et al.  Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block , 2006, Nature Immunology.

[31]  Mark Munsell,et al.  Engraftment of Acute Myeloid Leukemia in NOD/SCID Mice Is Independent of CXCR4 and Predicts Poor Patient Survival , 2004, Stem cells.

[32]  T. Lister,et al.  Mutation of CEBPA in familial acute myeloid leukemia. , 2004, The New England journal of medicine.

[33]  D. Catovsky,et al.  Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia , 2005, Leukemia.

[34]  T. Golub,et al.  c-Myc Is a Critical Target for C/EBPα in Granulopoiesis , 2001, Molecular and Cellular Biology.

[35]  O. MacDougald,et al.  A 30-kDa alternative translation product of the CCAAT/enhancer binding protein alpha message: transcriptional activator lacking antimitotic activity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[37]  Christian Steidl,et al.  Essential role of Jun family transcription factors in PU.1 knockdown–induced leukemic stem cells , 2006, Nature Genetics.

[38]  L. Shih,et al.  Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. , 2002, Blood.